Compare ZJYL & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZJYL | CYCN |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.8M | 16.6M |
| IPO Year | 2020 | N/A |
| Metric | ZJYL | CYCN |
|---|---|---|
| Price | $1.93 | $3.49 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 13.0K | ★ 18.5K |
| Earning Date | 08-20-2025 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $18.40 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.10 | $1.03 |
| 52 Week High | $4.50 | $8.48 |
| Indicator | ZJYL | CYCN |
|---|---|---|
| Relative Strength Index (RSI) | 46.73 | 45.10 |
| Support Level | $0.16 | $2.93 |
| Resistance Level | $2.59 | $3.97 |
| Average True Range (ATR) | 0.18 | 0.17 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 14.06 | 14.72 |
Jin Medical International Ltd, along with its subsidiaries, mainly offers rehabilitation equipment. It is engaged in the design, development, manufacturing, and sales of wheelchairs and other assistive living aid products for use by people with disabilities or impaired mobility. The group's product offering includes wheelchairs and wheelchair components, oxygen concentrators, bathing machines, respiratory and walking aids, oxygen chambers, beauty instruments, and nano products, among others. Wheelchairs are currently its key revenue-generating product. The products are sold to dealers in Japan and China, and to some extent to dealers located in the United States, Canada, Australia, Korea, Israel, Singapore, and other regions. Geographically, the group generates maximum revenue from Japan.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. The company focuses on enabling the full therapeutic potential of next-generation sGC stimulators and neuropsychiatric diseases. Its pipeline products include Olinciguat, Praliciguat, and others.